Streetbeat News

Analyst Ratings

LRCX

Barclays analyst Raimo Lenschow has maintained an Equal-Weight rating on Lam Research (NASDAQ:LRCX) and increased the price target from $750 to $825.

Portfolio Pulse from Benzinga Newsdesk

January 25, 2024 | 12:16 pm

ISRG

Barclays analyst Matt Miksic has maintained an Overweight rating on Intuitive Surgical (NASDAQ:ISRG) and increased the price target from $385 to $430, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 25, 2024 | 12:13 pm

LKQ

JP Morgan analyst Samik Chatterjee has maintained an Overweight rating on LKQ Corporation (NASDAQ:LKQ) but has reduced the price target from $65 to $63.

Portfolio Pulse from Benzinga Newsdesk

January 25, 2024 | 12:08 pm

VC

JP Morgan analyst Ryan Brinkman has maintained a Neutral rating on Visteon (NASDAQ:VC) but has reduced the price target from $160 to $148.

Portfolio Pulse from Benzinga Newsdesk

January 25, 2024 | 12:06 pm

MGA

JP Morgan analyst Ryan Brinkman has maintained an Overweight rating on Magna International (NYSE:MGA) but reduced the price target from $80 to $77.

Portfolio Pulse from Benzinga Newsdesk

January 25, 2024 | 12:03 pm

VFC

VF Corporation (NYSE:VFC) received mixed analyst ratings with 2 bullish, 1 somewhat bullish, and 5 indifferent. The average 12-month price target was lowered by 15.31% to $18.75. Analysts from firms including JP Morgan, Evercore ISI Group, Goldman Sachs, Piper Sandler, Stifel, BMO Capital, Wedbush, and Telsey Advisory Group have adjusted their ratings and price targets, with some raising and others lowering their expectations. VF's financials show a market cap above industry average, a revenue decline of -1.5%, a net margin of -14.85%, an ROE of -18.3%, an ROA of -3.32%, and a high debt-to-equity ratio of 3.53.

Portfolio Pulse from Benzinga Insights

January 25, 2024 | 12:01 pm

KIDS

OrthoPediatrics (NASDAQ:KIDS) has been evaluated by 5 analysts in the last three months, with a shift towards a more bearish sentiment. The average 12-month price target has been reduced by 12.73% to $38.4, with a high estimate of $50.00 and a low of $31.00. Analysts from Truist Securities and JMP Securities have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. OrthoPediatrics is a medical device company focused on the pediatric orthopedic market, showing a revenue growth of 14.37% as of September 30, 2023, and a net margin of -11.49%. The company's ROE and ROA are -1.22% and -1.06% respectively, with a debt-to-equity ratio of 0.0.

Portfolio Pulse from Benzinga Insights

January 25, 2024 | 12:00 pm

JD

JD.com (NASDAQ:JD) has been analyzed by 6 analysts, showing a mix of bullish and neutral stances. The average 12-month price target is $43.0, up from $42.60, with a high of $67.00 and a low of $30.00. Analysts from Citigroup, Mizuho, Susquehanna, Benchmark, UBS, and Barclays have adjusted their price targets and ratings, reflecting changes in market dynamics and company performance. JD.com's financials show a solid revenue growth rate of 1.71% as of September 30, 2023, but it lags in net margin and ROE while excelling in ROA and debt management.

Portfolio Pulse from Benzinga Insights

January 25, 2024 | 12:00 pm

IPGP

IPG Photonics (NASDAQ:IPGP) received mixed analyst ratings with 4 bullish ratings in the past three months. The average 12-month price target is $123.75, down from the previous $132.50. Analysts from Seaport Global and Stifel have provided recent evaluations, with Stifel's Ruben Roy adjusting the price target from $145.00 to $120.00. IPG Photonics is a developer and manufacturer of high-performance fiber lasers and related products, with significant revenue from materials processing applications. The company's financials show a revenue decline of -13.64% over 3 months, but strong net margin (18.25%), ROE (2.3%), and ROA (2.05%), with a low debt-to-equity ratio (0.01).

Portfolio Pulse from Benzinga Insights

January 25, 2024 | 12:00 pm

APTV

Analysts have recently adjusted their ratings and price targets for Aptiv (NYSE:APTV), with six analysts offering opinions ranging from bullish to bearish. Over the past three months, there has been a shift towards a more cautious stance, with the current average 12-month price target at $101.00, down from the previous $115.00. Analysts from firms including JP Morgan, Baird, Morgan Stanley, Barclays, RBC Capital, and Piper Sandler have all lowered their price targets. Aptiv's financial performance shows strong market recognition, revenue growth, profitability, and effective asset utilization, with a market capitalization that surpasses industry averages and a notable net margin of 31.85%.

Portfolio Pulse from Benzinga Insights

January 25, 2024 | 12:00 pm